Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease
• Pulnovo Medical has enrolled the first two U.S. patients in its PULSE-LHD clinical trial at Henry Ford Hospital in Detroit. • The trial is conducted under an FDA Investigational Device Exemption (IDE) to evaluate pulmonary artery denervation for treating pulmonary hypertension associated with left heart disease. • This study is significant as it tests a novel medical device approach to managing complex heart failure and pulmonary hypertension conditions.
prnewswire.com


